These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 11364123)

  • 41. Test could reveal HIV infection in newborns.
    Nurs Stand; 1993 Mar 3-9; 7(24):17. PubMed ID: 8481288
    [No Abstract]   [Full Text] [Related]  

  • 42. Consensus Conference on Laboratory Markers in HIV Infections. Rome, Italy, January 1996.
    J Biol Regul Homeost Agents; 1995; 9(3):71-120. PubMed ID: 8967302
    [No Abstract]   [Full Text] [Related]  

  • 43. Transient HIV-specific T cells increase and inflammation in an HIV-infected patient treated with nivolumab.
    Le Garff G; Samri A; Lambert-Niclot S; Even S; Lavolé A; Cadranel J; Spano JP; Autran B; Marcelin AG; Guihot A
    AIDS; 2017 Apr; 31(7):1048-1051. PubMed ID: 28350581
    [No Abstract]   [Full Text] [Related]  

  • 44. Serum test to measure HIV levels.
    Am Fam Physician; 1996 Nov; 54(6):2122. PubMed ID: 8967317
    [No Abstract]   [Full Text] [Related]  

  • 45. Point of orgin: the discovery and spread of HIV.
    Prater AM
    Posit Aware; 2011; 23(1):22-4. PubMed ID: 21314023
    [No Abstract]   [Full Text] [Related]  

  • 46. Surrogate Markers of HIV: Strategies and Issues for Selection and Use. Proceedings of a symposium. Arlington, Virginia, October 12-14, 1994.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 2():S1-117. PubMed ID: 7552505
    [No Abstract]   [Full Text] [Related]  

  • 47. Trends in HIV viral load.
    AIDS Read; 2000 Oct; 10(10):578. PubMed ID: 11068797
    [No Abstract]   [Full Text] [Related]  

  • 48. Bibliography. Biomarkers of outcomes of disease, treatment and complication. Current world literature.
    Curr Opin HIV AIDS; 2010 Nov; 5(6):560-4. PubMed ID: 20966641
    [No Abstract]   [Full Text] [Related]  

  • 49. Exploring other surrogate markers.
    Cohen J
    Science; 1992 Oct; 258(5081):389. PubMed ID: 17833119
    [No Abstract]   [Full Text] [Related]  

  • 50. FDA okays surrogate markers.
    Science; 1993 Jan; 259(5091):32-3. PubMed ID: 17757464
    [No Abstract]   [Full Text] [Related]  

  • 51. Molecular biological assessment methods and understanding the course of the HIV infection.
    Katzenstein TL
    APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 53. HIV surrogate markers: new virologic and immunologic indicators.
    MacDougall DS
    J Int Assoc Physicians AIDS Care; 1997 Mar; 3(3):15-7. PubMed ID: 11364123
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
    Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Retinal microangiopathy in human immunodeficiency virus infection is related to higher human immunodeficiency virus-1 load in plasma.
    Furrer H; Barloggio A; Egger M; Garweg JG;
    Ophthalmology; 2003 Feb; 110(2):432-6. PubMed ID: 12578793
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Use and access to viral load measure assays: the need for validation.
    Agosto M
    Update Natl Minor AIDS Counc; 1995; ():7-8. PubMed ID: 11362791
    [TBL] [Abstract][Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.